Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells. Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed. The JAK/STAT signalling pathway provides an example of this paradigm in haematological malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clinically effective JAK2 inhibitors, such as ruxolitinib. It is now clear that many solid tumours also show activation of JAK/STAT signalling.
Drug targets for cancer: JAK2 research reagents
Other vital drug targets for cancer likeJAK2:
Thomas S J, et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours[J]. British journal of cancer, 2015, 113(3): 365-371.